XFOR

Business Context and Reporting Period

Company: X4 Pharmaceuticals, Inc. (XFOR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: X4 is a biopharmaceutical company focused on rare immune system diseases. In April 2024, the FDA approved its lead product, XOLREMDI (mavorixafor), for the treatment of WHIM syndrome. The company launched the product in the U.S. in May 2024. X4 is also advancing mavorixafor for chronic neutropenic disorders via the pivotal Phase 3 "4WARD" trial.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The 2024 Net Loss was significantly reduced by a one-time $105 million gain from the sale of a Priority Review Voucher (PRV). Excluding this gain, the company incurred substantial operating losses.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded its first product revenue of $2.6 million following the May 2024 launch of XOLREMDI, compared to zero revenue in 2023.
• Expense Increases: SG&A expenses increased by $26.0 million (73%) primarily due to the build-out of the U.S. commercial team and marketing for XOLREMDI. R&D expenses increased by $9.6 million due to higher unallocated personnel costs.
• Debt Expansion: Borrowings under the Hercules Loan Agreement increased by $20.0 million during 2024, bringing total outstanding principal to $75.0 million.
• One-Time Gain: A $105 million gain was recognized from the sale of a PRV awarded by the FDA for the Rare Pediatric Disease designation of XOLREMDI. This was a non-recurring event.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary & Outlook

• 2025 Restructuring: In February 2025, the company announced a strategic restructuring to reduce annual spending by $30–$35 million. This includes a 30% reduction in headcount (43 employees), closing the Vienna, Austria facility, and pausing pre-clinical programs (X4P-002, X4P-003) to focus on mavorixafor.
• Liquidity: Management estimates the restructuring will provide sufficient funds to support operations into the first half of 2026.
• International Expansion: In January 2025, X4 entered an exclusive licensing agreement with Norgine for Europe, Australia, and New Zealand, receiving a €28.5 million upfront payment. An MAA for XOLREMDI is under review by the EMA.

Risks and Contingencies

• Going Concern: The company has raised "substantial doubt" about its ability to continue as a going concern. Current cash flows from operations are negative, and product sales are not yet sufficient to fund operations. Additional capital is required.
• Debt Covenant Risk: The Hercules Loan Agreement requires maintaining a minimum cash balance of 20% of outstanding borrowings ($15 million). Management believes there is a risk of violating this covenant within the next 12 months without additional financing or covenant modification.
• Nasdaq Compliance: The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00). It has received an extension until August 2025 to regain compliance, potentially via a reverse stock split.

Investor Verification Checklist

• Debt Covenant Status: Verify if the company has secured additional financing or modified the Hercules Loan Agreement to avoid a default on the minimum cash covenant.
• Reverse Stock Split: Monitor the outcome of the proposed reverse stock split (1-for-15 to 1-for-30) to determine if Nasdaq delisting is avoided.
• Commercial Uptake: Assess early sales data for XOLREMDI to determine if revenue growth can offset the high burn rate without further dilution.
• Restructuring Execution: Confirm the completion of the workforce reduction and facility closures to validate the projected $30–$35 million annual cost savings.
• EMA Approval Timeline: Track the status of the Marketing Authorisation Application (MAA) with the European Medicines Agency, as this triggers further milestone payments and commercial potential.